Development of a Staphylococcus aureus reporter strain with click beetle red luciferase for enhanced in vivo imaging of experimental bacteremia and mixed infections
- PMID: 31723175
- PMCID: PMC6853927
- DOI: 10.1038/s41598-019-52982-0
Development of a Staphylococcus aureus reporter strain with click beetle red luciferase for enhanced in vivo imaging of experimental bacteremia and mixed infections
Abstract
In vivo bioluminescence imaging has been used to monitor Staphylococcus aureus infections in preclinical models by employing bacterial reporter strains possessing a modified lux operon from Photorhabdus luminescens. However, the relatively short emission wavelength of lux (peak 490 nm) has limited tissue penetration. To overcome this limitation, the gene for the click beetle (Pyrophorus plagiophtalamus) red luciferase (luc) (with a longer >600 emission wavelength), was introduced singly and in combination with the lux operon into a methicillin-resistant S. aureus strain. After administration of the substrate D-luciferin, the luc bioluminescent signal was substantially greater than the lux signal in vitro. The luc signal had enhanced tissue penetration and improved anatomical co-registration with infected internal organs compared with the lux signal in a mouse model of S. aureus bacteremia with a sensitivity of approximately 3 × 104 CFU from the kidneys. Finally, in an in vivo mixed bacterial wound infection mouse model, S. aureus luc signals could be spectrally unmixed from Pseudomonas aeruginosa lux signals to noninvasively monitor the bacterial burden of both strains. Therefore, the S. aureus luc reporter may provide a technological advance for monitoring invasive organ dissemination during S. aureus bacteremia and for studying bacterial dynamics during mixed infections.
Conflict of interest statement
L.S.M. has received grant support from AstraZeneca, MedImmune (a subsidiary of AstraZeneca), Pfizer, Boerhinger Ingelheim, Regeneron Pharmaceuticals, and Moderna Therapeutics, is a shareholder of Noveome Biotherapeutics, is a paid consultant for Armirall and Janssen Research and Development and is on the scientific advisory board of Integrated Biotherapeutics, which are all developing therapeutics against infections (including
Figures
Similar articles
-
A stable luciferase reporter plasmid for in vivo imaging in murine models of Staphylococcus aureus infections.Appl Microbiol Biotechnol. 2016 Apr;100(7):3197-206. doi: 10.1007/s00253-015-7229-2. Epub 2015 Dec 21. Appl Microbiol Biotechnol. 2016. PMID: 26685857
-
Direct continuous method for monitoring biofilm infection in a mouse model.Infect Immun. 2003 Feb;71(2):882-90. doi: 10.1128/IAI.71.2.882-890.2003. Infect Immun. 2003. PMID: 12540570 Free PMC article.
-
Monitoring bioluminescent Staphylococcus aureus infections in living mice using a novel luxABCDE construct.Infect Immun. 2000 Jun;68(6):3594-600. doi: 10.1128/IAI.68.6.3594-3600.2000. Infect Immun. 2000. PMID: 10816517 Free PMC article.
-
Pseudomonas aeruginosa and Staphylococcus aureus virulence factors as biomarkers of infection.Biol Chem. 2021 Sep 10;402(12):1565-1573. doi: 10.1515/hsz-2021-0243. Print 2021 Nov 25. Biol Chem. 2021. PMID: 34505460 Review.
-
Imaging of light emission from the expression of luciferases in living cells and organisms: a review.Luminescence. 2002 Jan-Feb;17(1):43-74. doi: 10.1002/bio.676. Luminescence. 2002. PMID: 11816060 Review.
Cited by
-
Intracellular escape strategies of Staphylococcus aureus in persistent cutaneous infections.Exp Dermatol. 2021 Oct;30(10):1428-1439. doi: 10.1111/exd.14235. Epub 2020 Nov 21. Exp Dermatol. 2021. PMID: 33179358 Free PMC article. Review.
-
In Vivo Prevention of Implant-Associated Infections Caused by Antibiotic-Resistant Bacteria through Biofunctionalization of Additively Manufactured Porous Titanium.J Funct Biomater. 2023 Oct 16;14(10):520. doi: 10.3390/jfb14100520. J Funct Biomater. 2023. PMID: 37888185 Free PMC article.
-
γδ T cell-intrinsic IL-1R promotes survival during Staphylococcus aureus bacteremia.Front Immunol. 2023 Jul 7;14:1171934. doi: 10.3389/fimmu.2023.1171934. eCollection 2023. Front Immunol. 2023. PMID: 37483624 Free PMC article.
-
Optimizing a high-sensitivity NanoLuc-based bioluminescence system for in vivo evaluation of antimicrobial treatment.mLife. 2023 Dec 20;2(4):462-478. doi: 10.1002/mlf2.12091. eCollection 2023 Dec. mLife. 2023. PMID: 38818266 Free PMC article.
-
YjbH contributes to Staphylococcus aureus skin pathology and immune response through Agr-mediated α-toxin regulation.Virulence. 2024 Dec;15(1):2399798. doi: 10.1080/21505594.2024.2399798. Epub 2024 Sep 9. Virulence. 2024. PMID: 39229975 Free PMC article.
